Cover Image
Market Research Report

Global Viral Partnering 2010-2016: Deal trends, players and financials

Published by Current Partnering, a division of Wildwood Ventures Limited Product code 246683
Published Content info
Delivery time: 1-2 business days
Price
Back to Top
Global Viral Partnering 2010-2016: Deal trends, players and financials
Published: September 1, 2016 Content info:
Description

The ‘Global Viral Partnering 2010-2016: Deal trends, players and financials’ report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Viral Partnering 2010 to 2016’ provides the full collection of Viral disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Viral partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Viral partnering agreement structure
  • Viral partnering contract documents
  • Top Viral deals by value
  • Most active Viral dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Viral disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Viral deals.

The report presents financial deal terms values for Viral deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Viral dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Viral dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Viral deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Viral dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Viral deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Viral partnering deals by specific Viral target announced since 2010. The chapter is organized by specific Viral therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Viral partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Viral partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Viral technologies and products.

Report scope

‘Global Viral Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Viral trends and structure of deals entered into by leading companies worldwide.

‘Global Viral Partnering 2010 to 2016’ includes:

  • Trends in Viral dealmaking in the biopharma industry since 2010
  • Analysis of Viral deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Viral deal contract documents
  • Comprehensive access to over 3500 Viral deal records
  • The leading Viral deals by value since 2010
  • Most active Viral dealmakers since 2010

The report includes deals for the following indications:

Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1 (Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio, Respiratory syncytial virus (RSV), Zika, plus other viral indications.

In ‘Global Viral Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Viral Partnering 2010 to 2016’ report provides comprehensive access to available deals and contract documents for over 1,500 viral deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise viral rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Viral Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Viral deal trends since 2010
  • Access Viral deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Viral partner companies
  • Comprehensive access to over 750 links to actual Viral deals entered into by the world's biopharma companies
  • Indepth review of Viral deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Viral opportunities
  • Uncover companies actively partnering Viral opportunities
Table of Contents
Product Code: CP2206vir

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Viral dealmaking

  • 2.1. Introduction
  • 2.2. Viral partnering over the years
  • 2.3. Viral partnering by deal type
  • 2.4. Viral partnering by industry sector
  • 2.5. Viral partnering by stage of development
  • 2.6. Viral partnering by technology type
  • 2.7. Viral partnering by therapeutic indication

Chapter 3 -Financial deal terms for Viral partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Viral partnering
  • 3.3. Viral partnering headline values
  • 3.4. Viral deal upfront payments
  • 3.5. Viral deal milestone payments
  • 3.6. Viral royalty rates

Chapter 4 - Leading Viral deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Viral partnering
  • 4.3. List of most active dealmakers in Viral
  • 4.4. Top Viral deals by value

Chapter 5 - Viral contract document directory

  • 5.1. Introduction
  • 5.2. Viral partnering deals where contract document available

Chapter 6 - Viral dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Viral therapeutic target

Appendices

  • Appendix 1 - Directory of Viral deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Viral deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Viral deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Viral deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Viral partnering since 2010
  • Figure 2: Viral partnering by deal type since 2010
  • Figure 3: Viral partnering by industry sector since 2010
  • Figure 4: Viral partnering by stage of development since 2010
  • Figure 5: Viral partnering by technology type since 2010
  • Figure 6: Viral partnering by indication since 2010
  • Figure 7: Viral deals with a headline value
  • Figure 8: Viral deals with upfront payment values
  • Figure 9: Viral deals with milestone payment
  • Figure 10: Viral deals with royalty rates
  • Figure 11: Active Viral dealmaking activity- 2010 to 2016
  • Figure 12: Top Viral deals by value since 2010
Back to Top